Long COVID-19 Neuropeptide and Cytokine Expression in 90 Patients

90 patients with long COVID-19 were screened for neuropsychological sequelae, with experimental data showing upregulated expression of IL-6, IL-10, and Substance P (SP). The study includes patient demographics, symptom persistence durations, and computational drug screening results for NK1R antagonists. Data originates from a clinical study by Muhammad Abdullah, published in 2026.

Use Cases

• Analyze correlations between upregulated IL-6, IL-10, and SP levels and reported symptoms like fatigue, headache, and anxiety.
• Model the relationship between symptom persistence duration (e.g., 19 ± 6 weeks, 44 ± 6 weeks) and cytokine expression levels across patient age groups.
• Validate computational drug screening results for aprepitant and N-acetyl-L-tryptophan against NK1R using the reported binding affinities and molecular dynamics stability metrics (RMSD, RMSF, Rg).
• Investigate demographic distributions (60% male, 40% female, mean ages 33±5 and 58±10 years) across symptomatic and asymptomatic long COVID-19 groups.

Strengths

• Includes experimental biomarker data (IL-6, IL-10, SP) from 90 patients with quantified expression differences (p < 0.001).
• Reports detailed patient demographics and symptom prevalence percentages (e.g., 48% fatigue, 47% headache).
• Provides specific computational chemistry results for drug candidates, including binding affinities (-9.3 kcal/mol, -8.7 kcal/mol) and stability metrics.

Limitations

• Dataset is contained within a 2.3 MB DOCX file, not a structured, machine-readable table, limiting direct computational analysis.
• Sample size of 90 patients is relatively small for robust subgroup analyses or generalizable modeling.
• Lacks raw, row-level patient data; findings are presented as aggregated study results and summaries.

Provenance

Source

figshare, author Muhammad Abdullah.

Collection Method

Clinical screening and blood sample analysis (ELISA, RT-qPCR) of patients, combined with in silico virtual screening of nine drugs.

Time Range

Study period not specified; data reflects long COVID-19 symptoms persisting for durations reported as 19±6 weeks and 44±6 weeks.

Freshness

Last updated March 2026.

Geography

null